PATENT CLAIM ANALYSIS

Application Number: 16243301
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["546", "113000"]

Abstract:
Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.

Claim (Index 35):
A method of treating cancer responsive to inhibition of Raf kinase and/or Raf kinase dimer comprising administering to a subject in recognized need thereof at least one compound of any one of  claims 1 - 32  in an amount effective to inhibit said Raf kinase and/or Raf kinase dimer.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 99.0
- Lexical Diversity: 1.17647
- Patent Class: 546.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15882067', '14901634', '14901556', '14369379', '15882064']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8260481315564905
- 35 USC 102 Novelty (BERT): 0.5728196615634366
- Combined Prediction Score: 0.8007252845571851
- Mean Citation Score: 493.518814
- Max Citation Score: 517.0235
- Similarity Product: 385.9043982385695

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test